Latham & Watkins advised scPharmaceuticals on the deal. scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals’ $125 Million Senior Secured Term Loan
AbbVie’s Acquisition of Cerevel Therapeutics
Kirkland & Ellis advised AbbVie, Latham & Watkins advised Cerevel Therapeutics, Skadden advised Centerview partners LLC, as financial advisor to Cerevel Therapeutics in the transaction. AbbVie...
Ascendis Pharma’s $150 Million Royalty Funding Agreement with Royalty Pharma
Latham & Watkins and Mazanti-Andersen acted as legal advisors to Ascendis on the transaction, while Goodwin Procter, Kromann Reumert and Fenwick & West acted as legal...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
NewLimit’s $40 Million Series A Funding Round
Latham & Watkins represented NewLimit in the financing. NewLimit has announced that it has raised $40 million in a Series A funding round from Dimension, Founders Fund,...
Coherus BioSciences’ $57.5 Million Follow-On Offering
Latham & Watkins advised Coherus BioSciences, and Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. on the offering. Coherus BioSciences, Inc. (“Coherus”, Nasdaq:...
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Bionano Genomics’ Acquisition of Purigen Biosystems
Latham & Watkins LLP represented Purigen in the transaction. Bionano Genomics, Inc. (NASDAQ: BNGO) has entered into a definitive agreement to acquire Purigen Biosystems, Inc., a...
Merck’s $1.35 Billion Acquisition of Imago BioSciences, Inc.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Octagon Therapeutics’ Research Alliance with Novo Nordisk
Latham & Watkins represented Octagon Therapeutics in the transaction. Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, has announced the initiation of a...